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Epithelial–myoepithelial carcinoma (EMC) is a
rare type of malignant tumor, accounting for
about 1% of all salivary gland tumors 1;2 and rec-
ognizes a typical biphasic pattern: a central duc-
tular structures, often containing eosinophilic
material surronded by clear cells of myoepithelial
origin.
It was firstly described as a glycogen-rich or
clear cell adenoma because of the clear cell com-
ponent. Donath et al. 3 noted that the myoepi-
thelial component was an integral part of the
tumour and in 1972 he introduced the term epi-
thelial–myoepithelial carcinoma.* Corresponding author. Address: Department of Head and
Neck Surgery, 2nd University of Naples, Piazza Miraglia, 80100
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doi:10.1016/j.ooe.2003.12.003In 1991, the WHO recognized EMC as a distinct
entity and subtype of salivary gland adenocarci-
noma, and it became part of the new classification
system.4
The major salivary glands, especially the parotid
gland, are the most frequent site; however, cases
arising in minor salivary glands and extraoral areas
have been reported.5–8
The case reported by us concerned a 78-year-old
woman which showed a mass in the parotid gland of
13 cm in the largest dimension, with involvement
of skin.Case report
A 78-year-old woman presented with a mass in
the left parotid gland that had been a slowly
enlarging for 2 years.
At the time of the occurrence she had a 13 · 10
cm swelling in front of the tragus with involvementved.
Figure 1 Tumor mass (13 cm) in the left parotid with involvement of skin tissue and CT image.
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peared a bulky and, bossilated mass. There were no
palpable nodes or facial nerve palsy.
Except for a known hypertension, the medical
history was unremarkable.
A fine-needle aspiration biopsy was performed
(FNAB) and the cytologic specimen contained some
inflammatory, pleomorphic and clear epithelial
cells so that the diagnosis of clear cells tumor of
uncertain origin was carried out.
A preoperative CT showed the mass extension
and slightly nonhomogeneous signal intensity (Fig.
1b). In exploring, the tumour was infiltrating the
facial nerve.
A radical parotidectomy with full-thickness
excision of skin, modified neck dissection was
carried out and a reconstruction with cervical flap
was done.
Postoperatively she was treated with adjuvant
radiotherapy and remained disease-free for the
following 6 months.
Histological material was fixed in 10% buffered
formalin, then routinely processed and embedded
in paraffin.
Histological sections were stained with haema-
toxilin–eosin and PAS.Figure 2 (a) Typical morphological picture (PAS-hematoxylin
cells (ABC, 250X).The immunostaining was performed on paraffin
sections using ABC method (DAKO), according to
Hsu et al. 9 with DAB as chromogen.
Monoclonal antibodies (DAKO) to cytokeratin,
EMA, S100, secretory component, smooth muscle
actin, vimentin, GFAP were employed by us a pri-
mary antisera.
The omission and inversion of the primary anti-
sera were carried out as negative controls. Paraffin
sections of other tissues were used as positive
controls.
Macroscopically, parotid gland was character-
ized by a presence of a multilobular mass partially
capsulated and well circumscribed of 13 cm in
largest dimension, with scanty residual parotid
gland at periphery.
The tumor was formed by nests, sheets and tu-
bules, separated by thin stromal connective tissue
and characterized by the typical biphasic pattern:
central ductular structures, generally containing
eosinophilic material surrounded by clear cells.
Eosinophilic basal membranes, more evident
with PAS staining, surrounded the aggregates of
tumor cells (Fig. 2a).
The ductal cells were cuboidal with round nuclei
and eosinophilic cytoplasm., 250X). (b) Staining for actin in peripheral myoepithelial
Figure 3 (a) Staining for EMA is identifiable in inner epithelial layer (ABC, 250X). (b) Apical staining for secretory
component in inner epithelial layer (ABC, 250X).
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with irregularly shaped nuclei and indistinct cy-
toplasmatic borders. These cells were mainly
polygonal but sometimes spindle shaped or elon-
gated. The ratio of clear cells to ductal cells was
very variable within the tumor, so that the pro-
portion of clear cells ranged from 80 to
50%.Central necrosis of cellular aggregates was
sometimes observed. Cytological atypia was mild
or absent. Mitotic figures were less than 2 per 10
high power fields.
Immunohistochemistry highlighted the biphasic
pattern of tumor, because clear cells displayed
intense positivities for actin (Fig. 2b) and S100
protein and focal staining for GFAP.
On the contrary epithelial ductal cells showed
intensive staining only for cytocheratin and EMA
(Fig. 3a), whereas secretory component staining
was mainly detected as apical positivities on the
luminal borders (Fig. 3b) or within the material
included into the lumens.
Vimentin positivities were only identified in the
stromal tissue.Discussion and conclusions
The first description of EMC as a malignancy is
accredited to Donath et al. 3. It is a low-grade
malignant tumor that may commonly recur locally
after resection, but distant metastases rarely
occur.6–8
Statistics from the Armed Forces Institute of
Pathology reveal that the parotid gland is the most
commonly involved site, followed by the sub-
mandibular gland and palate as well as it ranges in
size from 1 to 12 cm.8
The case presented revealed an exceptional
size, reaching 13 cm in largest dimension and in-
volved adjacent skin tissue which displayed hem-orrhagic and ulcerated areas simulating an high
grade carcinoma of salivary glands.
The morphologic appearance of EMC poses the
intriguing question of the histogenesis.
Donath et al. postulated that the cell of origin
was from intercalated ducts.3;4
The occurrence of intercalated duct hyperplasia
has been observed in association with EMC in the
case described by Di Palma 11 and in three of
the cases described by Chetty 12. The integration of
the two elements probably means that the EMC
started from preceding intercalated duct hyper-
plasia.12;13
An additional feature of EMC is its association
with hybrid tumours of salivary gland.4
However, Grenko et al. examined some cases of
adenoid cystic carcinoma (ACC) and EMC-like foci
and cases of EMC with ACC-like foci, suggestive of
anomalous differentiation.13;14
The association of EMC with other salivary gland
tumours may also be a reflection of a common
differentiation pathways as suggested by multidi-
rectional differentiation that may be mediated
through intercalated duct hyperplasia.11;12;14
Morphologically EMC express both epithelial and
myoepithelial differentiation. Tumour presents as
bulky, lobulated, slow-growing mass becoming
large.8;15
Tumor myoepithelial phenotype has been cited
as a reason why tumors generally grow in a bulky
lobulated fashion, rather than in infiltrating
pattern.8;14–16
Infact, myoepithelial cells are known to secrete
low levels of matrix-degrading proteinases and an
excess of proteinase inhibitors.14
CT and MR appearances of EMC are nonspecific,
and that EMC cannot be differentiated from other
parotid neoplasms.17
The pathologic differential diagnosis includes
other clear cell salivary tumors as clear cell car-
cinoma, acinar cell carcinoma, mucoepidermoid
32 G. Colella et al.carcinoma, metastatic renal cell carcinoma, clear
cell oncocytoma and pleomorphic adenoma.4–8
However the case observed by us displays a
typical morphologic pattern and immunohisto-
chemical findings showed a specific biphasic pat-
tern characterized by peripheral clear cells (S100+,
actin+) of myoepithelial origin and inner layer of
cells of ductal origin (EMA+, Keratin+). Particularly,
this layer also showed apical positivities for secre-
tory component, as an evidence of its ductal origin.
The usual treatment is wide surgical resection,
including adjacent lymph nodes; adequate resec-
tion with negative soft-tissue margins is the mini-
mum recommended therapy.15
Recurrences have been analyzed4;8;10 from 9
months to two decades after initial resection.
Distant metastases to kidney, lung, and brain have
also been reported.4–8;10;13–15
In conclusion, once the diagnosis of EMC is
made, clinician must be vigilant concerning peri-
odic postoperative imaging because of the high
rate of local recurrence.References
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